The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIDP.L Regulatory News (IDP)

  • There is currently no data for IDP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.3 - [InnovaDerma plc]

2 Feb 2021 16:12

Form 8.3 - [InnovaDerma plc]

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”)

1. KEY INFORMATION

(a) Full name of discloser:OCTOPUS INVESTMENTS LTD
(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. 
(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offereeInnovaDerma plc
(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: 
(e) Date position held/dealing undertaken: For an opening position disclosure, state the latest practicable date prior to the disclosure01/02/2021
(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer? If it is a cash offer or possible cash offer, state “N/A”N/A

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security: Ordinary 10p
InterestsShort positions
 Number%Number%
(1) Relevant securities owned and/or controlled: 749,385 5.17  
(2) Cash-settled derivatives:     
(3) Stock-settled derivatives (including options) and agreements to purchase/sell:    
TOTAL:749,3855.17  

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b) Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists: 
Details, including nature of the rights concerned and relevant percentages: 

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a) Purchases and sales

Class of relevant securityPurchase/sale Number of securitiesPrice per unit
   

(b) Cash-settled derivative transactions

Class of relevant securityProduct descriptione.g. CFDNature of dealinge.g. opening/closing a long/short position, increasing/reducing a long/short positionNumber of reference securitiesPrice per unit
     

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

Class of relevant securityProduct description e.g. call optionWriting, purchasing, selling, varying etc.Number of securities to which option relatesExercise price per unitTypee.g. American, European etc.Expiry dateOption money paid/ received per unit
        

(ii) Exercise

Class of relevant securityProduct descriptione.g. call optionExercising/ exercised againstNumber of securitiesExercise price per unit
    

(d) Other dealings (including subscribing for new securities)

Class of relevant securityNature of dealinge.g. subscription, conversionDetailsPrice per unit (if applicable)
    

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”
None

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:(i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:If there are no such agreements, arrangements or understandings, state “none”
None

(c) Attachments

Is a Supplemental Form 8 (Open Positions) attached?NO

Date of disclosure:02/02/2021
Contact name:Lucy Wadsworth
Telephone number:020 3142 4081

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

Date   Source Headline
15th Oct 20202:00 pmRNSPrice Monitoring Extension
30th Sep 20207:00 amRNSFinal Results
28th Sep 20207:00 amRNSUS distributor appointed and Nuthing launch in AUS
18th Sep 20207:00 amRNSNotice of Results and Presentation
1st Sep 20209:37 amRNSHolding(s) in Company
12th Aug 202010:58 amRNSHolding(s) in Company
5th Aug 20209:15 amRNSDirectorate Change
31st Jul 202010:22 amRNSHolding(s) in Company
13th Jul 20209:40 amRNSHolding(s) in Company
10th Jul 20207:00 amRNSTrading Statement
1st Jul 202010:10 amRNSHolding(s) in Company
12th Jun 20205:57 pmRNSHolding(s) in Company
26th May 20207:00 amRNSTrading Statement
13th May 20204:42 pmRNSHolding(s) in Company
7th May 202010:52 amRNSDirector/PDMR Shareholding
6th May 202010:05 amRNSHolding(s) in Company
4th May 202011:09 amRNSHolding(s) in Company
30th Apr 202011:05 amRNSSecond Price Monitoring Extn
30th Apr 202011:00 amRNSPrice Monitoring Extension
6th Apr 20202:05 pmRNSSecond Price Monitoring Extn
6th Apr 20202:00 pmRNSPrice Monitoring Extension
6th Apr 20207:00 amRNSCOVID-19 Update
23rd Mar 20207:00 amRNSDirector/PDMR Shareholding
18th Mar 20201:56 pmRNSDirector/PDMR Shareholding
17th Mar 20201:52 pmRNSHolding(s) in Company
16th Mar 202012:54 pmRNSDirector/PDMR Shareholding
12th Mar 20202:37 pmRNSDirector/PDMR Shareholding
12th Mar 202011:06 amRNSSecond Price Monitoring Extn
12th Mar 202011:00 amRNSPrice Monitoring Extension
3rd Mar 202010:47 amRNSDirector/PDMR Shareholding
25th Feb 202011:52 amRNSHalf-year Report- Replacement
25th Feb 20207:00 amRNSHalf-year Report
24th Feb 20207:00 amRNSInnovaDerma launches new brand "Nuthing"
3rd Feb 20207:00 amRNSNotice of Results
23rd Jan 20208:48 amRNSGrant of Options/PDMR Dealing
9th Jan 20207:00 amRNSTrading Statement
5th Dec 20197:00 amRNSDTC channel delivers best Black Friday weekend
29th Nov 20192:26 pmRNSDirector/PDMR Shareholding
28th Nov 20193:21 pmRNSDirector/PDMR Shareholding
20th Nov 20197:00 amRNSLaunch of new Skinny Tan 'Choc' range in Superdrug
13th Nov 201912:39 pmRNSDirector/PDMR Shareholding
8th Nov 20193:40 pmRNSDirector/PDMR Shareholding
8th Nov 20193:22 pmRNSDirector/PDMR Shareholding
7th Nov 20192:33 pmRNSHolding(s) in Company
7th Nov 20191:55 pmRNSHolding(s) in Company
7th Nov 20191:53 pmRNSDirector/PDMR Shareholding
7th Nov 20191:47 pmRNSDirectorate Change
6th Nov 201911:01 amRNSResult of AGM
6th Nov 20197:00 amRNSAGM Statement
31st Oct 20197:00 amRNSLaunch of new category in Superdrug

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.